Hypercalcemia during Long-Term Treatment with 1,25-Dihydroxyvitamin D3 in Hypoparathyroidism

N. H. Bell, S. Epstein, P. H. Stern

Research output: Contribution to journalLetterpeer-review

5 Scopus citations


To the Editor: We previously reported on two patients with pseudohypoparathyroidism who were receiving long-term maintenance treatment with 1,25-dihydroxyvitamin D3 (l,25(OH)2D3), and who had spontaneous hypercalcemia and increases in serum l,25(OH)2D.1 These abnormalities were corrected by stopping the drug, and recurrences were prevented by subsequent reduction of the dosage. We have recently observed a similar sequence of events in a patient with hypoparathyroidism. A 75-year-old woman with hypercalcemia, impaired renal function, and a normal level of serum immunoreactive parathyroid hormone (PTH), had noncaseating granulomas in lymph nodes obtained during mediastinal exploration and excision. No extract is available for articles shorter than 400 words.

Original languageEnglish (US)
Pages (from-to)1183-1184
Number of pages2
JournalNew England Journal of Medicine
Issue number21
StatePublished - Nov 22 1979

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Hypercalcemia during Long-Term Treatment with 1,25-Dihydroxyvitamin D3 in Hypoparathyroidism'. Together they form a unique fingerprint.

Cite this